...
首页> 外文期刊>Journal of viral hepatitis. >Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.
【24h】

Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.

机译:慢性丙型肝炎感染对干扰素治疗的生化反应与病毒学反应之间的关系。共识干扰素研究组。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We have investigated the relationship between serum alanine aminotransferase (ALT) and hepatitis C virus (HCV) RNA in the assessment of responses to interferon (IFN) therapy in chronic HCV infection. Data from 704 patients with HCV infection who were randomized to receive consensus IFN-alpha (CIFN) 3 micrograms (n = 232 patients) or 9 micrograms (n = 232 patients), or IFN-alpha 2b 3 million units (MU) (n = 240 patients), were used for these analyses. All patients were treated three times weekly. Hepatitis C viral RNA (HCV RNA) was determined by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) with a lower limit of detection of 100 copies ml-1. Of patients with normal serum ALT concentrations, 53% (120/225) had undetectable HCV RNA at the end-of-treatment period and 47% (51/109) had undetectable HCV RNA at the end of the post-treatment observation period. In contrast, of the patients with undetectable HCV RNA, 75% (120/161) and 84% (51/61) had normal serum ALT activities at the end-of-treatment and post-treatment observations periods, respectively. The majority of patients with undetectable HCV RNA had normal ALT values. In contrast, only half of the patients with normal ALT values were negative for HCV. End-of-treatment HCV RNA response also better predicted sustained virological response than did end-of-treatment ALT response.
机译:我们在评估慢性HCV感染对干扰素(IFN)治疗的反应中,研究了血清丙氨酸氨基转移酶(ALT)和丙型肝炎病毒(HCV)RNA之间的关系。来自704例HCV感染患者的数据,他们随机接受3毫克IFN-α(n = 232例患者)或9毫克(n = 232例)或IFN-alpha 2b 300万单位(MU)(n = 240位患者)用于这些分析。所有患者每周接受三次治疗。丙型肝炎病毒RNA(HCV RNA)通过定量逆转录酶-聚合酶链反应(RT-PCR)测定,检测下限为100份ml-1。在血清ALT浓度正常的患者中,有53%(120/225)在治疗结束时检测不到HCV RNA,47%(51/109)在治疗后观察期结束时检测不到HCV RNA。相反,在HCV RNA检测不到的患者中,分别在治疗结束和治疗后观察期,血清ALT活性正常,分别为75%(120/161)和84%(51/61)。 HCV RNA检测不到的大多数患者的ALT值均正常。相反,只有ALT值正常的患者中有一半是HCV阴性的。与治疗结束后的ALT应答相比,治疗结束后的HCV RNA应答也更好地预测了持续的病毒学应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号